Redhill Biopharma (NASDAQ:RDHL – Get Free Report) is expected to be posting its H1 2026 resultson Thursday, August 20th. Analysts expect the company to announce earnings of ($435.00) per share and revenue of $22.7030 million for the quarter. Individuals may visit the the company’s upcoming H1 2026 earning report for the latest details on the call scheduled for Thursday, August 27, 2026 at 12:30 PM ET.
Redhill Biopharma Stock Performance
NASDAQ RDHL opened at $0.59 on Wednesday. Redhill Biopharma has a one year low of $0.57 and a one year high of $2.79. The company has a market capitalization of $3.60 million, a price-to-earnings ratio of 0.00 and a beta of 5.00. The company’s 50-day simple moving average is $0.73 and its two-hundred day simple moving average is $0.87.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a research note on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Redhill Biopharma has a consensus rating of “Sell”.
About Redhill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.
RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.
Read More
- Five stocks we like better than Redhill Biopharma
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
